Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260377 | 1.00 | DGAT1 (0.34) | DGAT1ALDH1A1HPGD | |
| SCHEMBL1542636 | 1.00 | DGAT1 (0.34) | DGAT1ALDH1A1HPGD | |
| SCHEMBL796349 | 0.89 | DGAT1 (0.40) | DGAT1ALDH1A1HPGD | |
| SCHEMBL77788 | 0.89 | DGAT1 (0.40) | DGAT1ALDH1A1HPGD | |
| SCHEMBL77789 | 0.89 | DGAT1 (0.40) | DGAT1ALDH1A1HPGD | |
| SCHEMBL25292338 | 0.82 | ELANE (0.32) | DGAT1 | |
| SCHEMBL19406048 | 0.81 | CYP2D6 (0.30) | — | |
| SCHEMBL15843648 | 0.80 | DGAT1 (0.44) | DGAT1ALDH1A1HPGD | |
| SCHEMBL15843647 | 0.80 | DGAT1 (0.44) | DGAT1ALDH1A1HPGD | |
| SCHEMBL20278337 | 0.80 | DGAT1 (0.34) | DGAT1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025051214-A1 | AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR | 上海翊石医药科技有限公司 | 2025-03-13 | — | — | WO | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-112004913-B | Liquid crystal mixture and liquid crystal display | 默克专利股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118317793-A | Methods for treating brain tumors and neuroblastomas | 阿斯利康(瑞典)有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240150375-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | THESEUS PHARMACEUTICALS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| EP-3784752-B1 | LIQUID CRYSTAL MIXTURE AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2024-04-17 | — | — | EP | disclosed |
| CN-117881682-A | 6-amino pyrazolopyrimidine compound and medical application thereof | 日本烟草产业株式会社 | 2024-04-12 | — | — | CN | disclosed |
| US-11939511-B2 | Liquid crystal mixture and liquid crystal display | MERCK PATENT GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| EP-4337665-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | Theseus Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2015058163-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| US-8829026-B2 | Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists | RAQUALIA PHARMA INC. (JP) | 2014-09-09 | — | — | US | disclosed |
| CN-103958502-A | Quinazoline compounds as serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC | 2014-07-30 | — | — | CN | disclosed |
| CN-102316733-B | Heterocyclic compounds and methods of use | GENENTECH INC | 2014-01-01 | — | — | CN | disclosed |
| US-20130210858-A1 | SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2013-08-15 | — | — | US | disclosed |
| CN-101421243-B | Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO KG | 2012-05-30 | — | — | CN | disclosed |
| WO-2012042915-A1 | SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-05 | — | — | WO | disclosed |
| CN-102316733-A | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INST MEDICAL W & E HALL | 2012-01-11 | — | — | CN | disclosed |
| EP-1635817-A1 | 1-PHENYL-2-OXO-3-SULFONYLAMINO-PYRROLIDINE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR XA INHIBITORS FOR THE TREATMENT OF ACUTE VASCULAR DISEASES | GLAXO GROUP LIMITED (GB) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110435-A1 | 1-PHENYL-2-OXO-3-SULFONYLAMINO-PYRROLIDINE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR XA INHIBITORS FOR THE TREATMENT OF ACUTE VASCULAR DISEASES | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | DGAT1 2605/4885ALDH1A1 2354/4885HPGD 2251/4885 |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | DGAT1 302/4885ALDH1A1 410/4885HPGD 312/4885 |
| US-20130210858-A1 | SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM6, TRPM5 | DGAT1 2061/4885ALDH1A1 2692/4885HPGD 1552/4885 |
| US-11939511-B2 | Liquid crystal mixture and liquid crystal display | CXCR1, PYM1, F11 | DGAT1 4302/4885ALDH1A1 2963/4885HPGD 3980/4885 |
| US-20240150375-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | EGFR, ERBB2, ERBB3 | DGAT1 2848/4885ALDH1A1 2665/4885HPGD 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.